Allred Capital Management LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.9% during the third quarter, Holdings Channel reports. The institutional investor owned 25,167 shares of the biopharmaceutical company’s stock after buying an additional 2,055 shares during the period. Allred Capital Management LLC’s holdings in Pfizer were worth $923,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently bought and sold shares of PFE. Corbett Road Capital Management LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $25,000. Reitz Capital Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Disciplined Investments LLC lifted its holdings in Pfizer by 43.3% in the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 347 shares in the last quarter. Rocky Mountain Advisers LLC lifted its holdings in Pfizer by 847.5% in the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,000 shares in the last quarter. Finally, JJJ Advisors Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $44,000. 69.08% of the stock is currently owned by hedge funds and other institutional investors.
PFE opened at $37.95 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $210.88 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 2.91 and a beta of 0.67. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $40.97. The business’s fifty day simple moving average is $36.59 and its 200-day simple moving average is $36.32.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The firm had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.80 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is currently 51.53%.
A number of research analysts recently commented on the company. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $44.00 to $39.00 in a report on Monday, October 12th. Piper Sandler boosted their price target on Pfizer from $18.50 to $24.00 in a report on Friday, June 26th. SVB Leerink boosted their price target on Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a report on Wednesday, July 29th. Morgan Stanley upped their price objective on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Finally, Berenberg Bank began coverage on Pfizer in a report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $39.64.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.08% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: What is Cost of Debt?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.